Analysts await Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.07 EPS, down 14.29% or $0.01 from last year’s $-0.06 per share.

At the moment 4 analysts are watching Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), 0 rate it “Buy”, 4 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 0.00 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 0.00 million whilst for the year ending Dec-16, 4 analysts have a mean target of 6.47 million.

In terms of earnings per share, 2 analysts have a -0.07 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 2 analysts have a -0.08 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of -0.29 EPS.

Total shares held by institutions as of the most recent company filings are 44,462,721 with a reported 4,042,840 bought and 3,892,102 sold. These holdings make up 71.68% of the company’s outstanding shares.

The stock increased 0.82% or $0.01 during the last trading session, hitting $6.00. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 31.17% over the past 6 months and is uptrending.